DKSH has entered into distribution agreement with Xcell Therapeutics, a specialist in chemically defined cell culture media, to strengthen access to advanced bioprocessing solutions in India. Through this partnership, DKSH will support Xcell Therapeutics’ growth in India’s rapidly expanding biotechnology and cytogenetic therapy market.
Mumbai, India, January 22, 2026 – DKSH’s Business Unit Performance Materials, a leading distributor of specialty chemicals and ingredients, has signed an distribution agreement with Xcell Therapeutics to market and distribute its flagship CellCor chemically defined media in India. Under the agreement, DKSH will provide comprehensive business development, marketing, sales, logistics, and distribution services to support Xcell Therapeutics’ expansion in the region.
Xcell Therapeutics is recognized for its expertise in developing high-quality, chemically defined media designed to support advanced cytogenetic therapy manufacturing. Its CellCor media is engineered to ensure consistency, scalability, and performance across next-generation biotechnology applications.
Through this partnership, DKSH will leverage its extensive local market knowledge, strong customer relationships, and technical capabilities to support Xcell Therapeutics in addressing the rising demand for reliable and innovative cell culture solutions.
Say Kim, Team Leader of Overseas Sales Team from Xcell Therapeutics commented: “Leveraging DKSH’s extensive network and specialized market entry expertise, we will be able to more efficiently identify new customers and respond to local regulatory requirements. This will minimize market entry risks and accelerate supply.”
Chinmay Mhaskar, Managing Director, DKSH India, commented: “We are delighted to partner with Xcell Therapeutics and expand our portfolio of advanced biotechnology solutions in India. With our deep market insights, strong distribution infrastructure, and dedicated technical support, we are well positioned to accelerate the adoption of Xcell Therapeutics’ CellCor media and create sustainable growth opportunities for both partners.”
About Xcell Therapeutics
Founded in 2015, Xcell Therapeutics (KOSDAQ: 373110) is a leading biotechnology company specializing in the development and manufacturing of chemically defined cell culture media, a critical raw material for the advanced cell therapy industry. Xcell Therapeutics has pioneered the world's first serum-free, chemically defined media for mesenchymal stem cells (MSCs) under the brand CellCor™. Leveraging its proprietary technology platforms, XPorT, the company provides animal-origin-free (AOF) and regulatory-friendly solutions that ensure superior safety and consistency in cell therapy production. We operate a state-of-the-art GMP facility in Yong-in with an annual production capacity of 40,000 liters, and its product is recognized with US FDA Drug Master File (DMF) registration and the "World Class Product of Korea" certification. With an expanding global distribution network, Xcell Therapeutics is committed to accelerating the commercialization of regenerative medicine through ethical and innovative science. www.xcell.media
About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution, and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Performance Materials distributes specialty chemicals and ingredients for food, pharmaceutical, personal care, and various industrial applications. With 58 innovation centers and regulatory support worldwide, DKSH creates cutting-edge formulations that comply with local regulations. With around 1,720 specialists, the Business Unit generated net sales of CHF 1.4 billion in 2024. www.dksh.com/pm